| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17425247.2012.729574 |
| P698 | PubMed publication ID | 23013384 |
| P2093 | author name string | Michael Soyka | |
| P2860 | cites work | The mechanistic classification of addictive drugs | Q21090144 |
| Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review | Q28295247 | ||
| 30 years of dynorphins--new insights on their functions in neuropsychiatric diseases | Q30481450 | ||
| A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo | Q33319639 | ||
| Opioids in the hypothalamus control dopamine and acetylcholine levels in the nucleus accumbens | Q33666303 | ||
| From research to the real world: buprenorphine in the decade of the Clinical Trials Network | Q33783274 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence | Q33870389 | ||
| The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse | Q33890721 | ||
| Effects of buprenorphine/naloxone in opioid-dependent humans | Q33946582 | ||
| The Neurobiology of Addiction: Where We Have Been and Where We Are Going | Q33980112 | ||
| Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. | Q34165511 | ||
| Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients | Q34172462 | ||
| Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. | Q34576029 | ||
| Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine | Q34650967 | ||
| Buprenorphine induces ceiling in respiratory depression but not in analgesia | Q34651926 | ||
| Opioid receptor PET reveals the psychobiologic correlates of reward processing | Q34796903 | ||
| Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence | Q34975842 | ||
| Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review | Q35160035 | ||
| Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films | Q35575641 | ||
| Endogenous opioids and addiction to alcohol and other drugs of abuse | Q35644189 | ||
| Buprenorphine in the treatment of opioid dependence | Q35729394 | ||
| Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study | Q35740495 | ||
| Reward processing by the opioid system in the brain. | Q35786247 | ||
| A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths | Q35841618 | ||
| An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research | Q36144599 | ||
| Drugs of abuse: anatomy, pharmacology and function of reward pathways | Q36208822 | ||
| Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction | Q36741881 | ||
| Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence | Q37079346 | ||
| Toxicity of buprenorphine overdoses in children. | Q37125396 | ||
| The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence | Q37587221 | ||
| The endogenous opioid system: a common substrate in drug addiction | Q37640872 | ||
| Methadone and buprenorphine toxicity in children | Q37687453 | ||
| Buprenorphine‐Based Regimens and Methadone for the Medical Management of Opioid Dependence: Selecting the Appropriate Drug for Treatment | Q37801439 | ||
| Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies | Q37807466 | ||
| A case series of buprenorphine/naloxone treatment in a primary care practice | Q37947698 | ||
| Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users | Q38475440 | ||
| Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study | Q40132985 | ||
| A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals | Q42608727 | ||
| Buprenorphine injection in Melbourne, Australia--an update | Q42645104 | ||
| Ventricular arrhythmias in patients treated with methadone for opioid dependence | Q43153232 | ||
| A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence | Q43593858 | ||
| 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial | Q44328541 | ||
| Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices | Q44331935 | ||
| Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia | Q44338226 | ||
| Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients | Q44340913 | ||
| Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers | Q44342476 | ||
| Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse | Q44346744 | ||
| Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing | Q45338870 | ||
| Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients | Q46705226 | ||
| A 24-year follow-up of California narcotics addicts | Q46733329 | ||
| Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. | Q51173415 | ||
| The quantification of mortality resulting from the regular use of illicit opiates. | Q52277271 | ||
| Drug-related mortality and its impact on adult mortality in eight European countries | Q57209662 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1409-1417 | |
| P577 | publication date | 2012-09-26 | |
| P1433 | published in | Expert Opinion on Drug Delivery | Q5421203 |
| P1476 | title | Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence | |
| P478 | volume | 9 |
| Q38683620 | Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations. |
| Q38243268 | Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update |
| Q34952233 | New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone |
Search more.